Sanofi ADR (SNY)
Sanofi ADR (SNY) carries a ŷRobot AI score of 46 out of 100. The model's fair value estimate is $44.88, 7.2% below the last close of $48.37. The chart signal reads Sell.
| Metric | SNY |
|---|---|
| AI score | 46 / 100 |
| Chart signal | Sell |
| Fair value estimate | $44.88 |
| Upside to fair value | -7.2% |
| Previous close | $48.37 |
| P/E | 22.06 |
| Price / sales | 1.79 |
| Market cap | $116.00B |
| EPS | 2.01 |
| Revenue growth | 7.0% |
| 1-year price change | -0.9% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about SNY
Is SNY overvalued or undervalued right now?
As of Nov 2, 2026, ŷRobot's fair-value model estimates Sanofi ADR (SNY) at $44.88 against a last close of $48.37, implying 7.2% downside to the model's estimate.
Is SNY's chart signal bullish or bearish?
The chart-signal model classifies SNY as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is SNY's ŷRobot AI score?
SNY scores 46 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is SNY stock expensive on P/E and P/S?
SNY trades at 22.1 times earnings and 1.8 times sales as of Nov 13, 2026.
What does SNY's seasonal forecast show?
ŷRobot's seasonal forecast curve for SNY reads -0.1% at 30 days, -0.8% at 90 days, and -0.9% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is SNY growing?
Sanofi ADR's revenue growth is +7.0% and free-cash-flow growth is +26.6% on the latest reported figures.
SNY chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.